Clinical description of 68 patients with MCL: comparison of nodal versus nonnodal leukemic MCL
. | Patients with MCL . | Nodal group . | Leukemic group . | P . |
|---|---|---|---|---|
| Patients | ||||
| No. | 68 | 57 | 11 | NA |
| Male; female | 49; 19 | 42; 15 | 7; 4 | NS |
| Median age, y (range) | 70 (46-86) | 69 (46-86) | 74 (49-77) | NS |
| Clinical features | ||||
| PB disease (%) | 28 (41) | 17 (30) | 11 (100) | < .001 |
| BM infiltration (%) | 40 (60) | 29 (52) | 11 (100) | .002 |
| Splenomegaly (%) | 29 (43) | 25 (45) | 4 (36) | NS |
| Waldeyer ring (%) | 5 (7) | 5 (9) | 0 (0) | NS |
| GI tract (%) | 9 (13) | 9 (16) | 0 (0) | NS |
| IPI 4 to 5 (%) | 8 (12) | 8 (14) | 0 (0) | NS |
| IgVH mutation (%) | 19 (28) | 12 (21) | 7 (64) | .009 |
| IgVH family | ||||
| VH3-23 (%) | 5 (7) | 4 (7) | 1 (9) | NS |
| VH3-21 (%) | 7 (10) | 7 (13) | 0 (0) | NS |
| VH3-34 (%) | 9 (13) | 8 (14) | 1 (9) | NS |
| VH3-59 (%) | 8 (12) | 6 (11) | 2 (18) | NS |
| VH4-39 (%) | 6 (9) | 2 (4) | 4 (36) | .005 |
| Cytology | ||||
| Blastoid (%) | 11 (16) | 11 (20) | 0 (0) | NS |
| Classic (%) | 57 (84) | 46 (81) | 11 (100) | NA |
| IPI 4 to 5 (%) | 8 (12) | 8 (14) | 0 (0) | NS |
| Median survival, mo | 39 | 18 | 42 | NA |
| Survival more than 36 mo (%) | 22 (33) | 15 (27) | 7 (64) | .02 |
| Genomic imbalances | ||||
| del(8)(p21.3) (%) | 17 (25) | 11 (19) | 6 (55) | .01 |
| gain 8q24-MYC (%) | 13 (19) | 8 (14) | 5 (46) | .015 |
. | Patients with MCL . | Nodal group . | Leukemic group . | P . |
|---|---|---|---|---|
| Patients | ||||
| No. | 68 | 57 | 11 | NA |
| Male; female | 49; 19 | 42; 15 | 7; 4 | NS |
| Median age, y (range) | 70 (46-86) | 69 (46-86) | 74 (49-77) | NS |
| Clinical features | ||||
| PB disease (%) | 28 (41) | 17 (30) | 11 (100) | < .001 |
| BM infiltration (%) | 40 (60) | 29 (52) | 11 (100) | .002 |
| Splenomegaly (%) | 29 (43) | 25 (45) | 4 (36) | NS |
| Waldeyer ring (%) | 5 (7) | 5 (9) | 0 (0) | NS |
| GI tract (%) | 9 (13) | 9 (16) | 0 (0) | NS |
| IPI 4 to 5 (%) | 8 (12) | 8 (14) | 0 (0) | NS |
| IgVH mutation (%) | 19 (28) | 12 (21) | 7 (64) | .009 |
| IgVH family | ||||
| VH3-23 (%) | 5 (7) | 4 (7) | 1 (9) | NS |
| VH3-21 (%) | 7 (10) | 7 (13) | 0 (0) | NS |
| VH3-34 (%) | 9 (13) | 8 (14) | 1 (9) | NS |
| VH3-59 (%) | 8 (12) | 6 (11) | 2 (18) | NS |
| VH4-39 (%) | 6 (9) | 2 (4) | 4 (36) | .005 |
| Cytology | ||||
| Blastoid (%) | 11 (16) | 11 (20) | 0 (0) | NS |
| Classic (%) | 57 (84) | 46 (81) | 11 (100) | NA |
| IPI 4 to 5 (%) | 8 (12) | 8 (14) | 0 (0) | NS |
| Median survival, mo | 39 | 18 | 42 | NA |
| Survival more than 36 mo (%) | 22 (33) | 15 (27) | 7 (64) | .02 |
| Genomic imbalances | ||||
| del(8)(p21.3) (%) | 17 (25) | 11 (19) | 6 (55) | .01 |
| gain 8q24-MYC (%) | 13 (19) | 8 (14) | 5 (46) | .015 |
GI indicates gastrointestinal; IPI, International Prognostic Index; NS, not significant; NA, not applicable.